Nucleate's Activator: Inside the Accelerator Program

Join Nucleate Rhode Island for a panel discussion featuring Rhode Island teams that participated in the Nucleate Activator program. The event will bring together students, researchers, faculty, founders, and members of the broader Rhode Island biotech community to explore how Nucleate supports the transition from academic research to entrepreneurship. This event will feature a panel discussion moderated by Devin Bemis, co-MD of the Nucleate Rhode Island chapter, with panelists representing Rhode Island teams that participated in the Boston Activator program during the 2025–2026 cycle. Panelists will introduce their companies and share their experiences in the Activator program, highlighting the skills, experiences, mentorship, and networks they gained through their participation. Arvin Soepriatna, PhD, co-founded TEEM Therapeutics, a 2026 Nucleate Activator Team Chathuraka “Chat” Jayasuriya, PhD, co-founder of EnkaBio, a 2026 Nucleate Activator Team David Zhou, PhD, co-founder of PyraSim Neuroscience, a 2025 Nucleate Boston Activator Team Haley Wexelblatt, M.D. Candidate at The Warren Alpert Medical School of Brown University, clinical contributor with AlVida Biosciences, a 2026 Nucleate Activator Team. The event will conclude with a Q&A session, followed by information on how future teams can apply to participate in the Activator program. About the Host: Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit www.nucleate.xyz for more information, and visit https://nucleate.xyz/privacy-policy/ to read our privacy policy.